Assessment of reactogenicity, safety and immunogenicity of the domestic vaccine «Encevir®» with the reduced antigenic load in the immunization of children aged 3-17 years accordingly to routine scheduled vaccination (report 2)

The article presents the results of an open comparative randomized clinical study on the assessment of the reactogenicity, safety and immunogenicity of the domestic vaccine "EntseVir®" with reduced antigenic load in immunization of children aged 3 to 17 years on the schedule for 0-60 days. The vaccine is characterized by the low reactogenicity, high safety profile and immunogenicity. On main indices, it is not inferior to foreign vaccine «FSME-Immun Inject / Junior».